NCT02912715已完成不适用
Prospective, Multi-center, Non-randomized Clinical Trial of Passeo-18 Lux Drug Coated Balloon（DCB） in New and Non-stented Re-stenotic Lesions in the Superficial Femoral Artery (SFA) and Proximal Popliteal Artery (PPA) in a Chinese Patient Population
Biotronik (Beijing) Medical Device Ltd.1 个研究点 分布在 1 个国家目标入组 158 人开始时间: 2016年10月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 158
- 试验地点
- 1
- 主要终点
- Major Adverse Events
研究概览
简要总结
Prospective, multi-center, non-randomized clinical trial with follow-up investigations at 1, 6 and 12 months. To confirm safety and efficacy of Passeo-18 Lux DCB in new and non-stented re-stenotic lesions in the superficial femoral artery (SFA) and proximal popliteal artery (PPA) in a Chinese patient population.
详细描述
A prospective, multi-centre, non-randomized clinical trial with follow-up investigations at 1, 6 and 12 months. Approximately 158 subjects will be enrolled at 15 Chinese study sites. To confirm the safety and efficacy of the Passeo-18 Lux DCB for the interventional treatment of new and non-stented re-stenotic lesions in the superficial femoral artery (SFA) and proximal popliteal artery (PPA) in a Chinese patient population.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years.
- •Subject with documented diagnosis of peripheral arterial disease (PAD) classified as Rutherford class 2-3-4 in the superficial femoral artery (SFA) and/or proximal popliteal artery (PPA) above the knee, located in the arterial segment starting at least 1 cm beyond the common femoral artery (CFA) bifurcation between the superficial and profunda femoris arteries (proximal anatomical landmark) to the distal P1 segment of the popliteal artery at the level of the proximal edge of the patella (distal anatomical landmark).
- •Subject able to walk without assistive devices (e.g. walker, cane).
- •Female subjects of childbearing potential must have a negative pregnancy test ≤ 7 days before index procedure; Both male and female subjects are willing to use a reliable method of birth control for the duration of the study or must have documented adequate birth control.
- •Signed and dated Patient Informed Consent (PIC) form.
- •Subject understands and accepts the duration of the study and is able and willing to comply with all requirements, including follow-up visits and evaluations.
- •Life expectancy, in the Investigator's opinion, of at least 12 months.
- •Target lesion consists of a de novo or non-stented restenotic lesion with a ≥70% diameter stenosis.
- •Lesion length≤ 200 mm.
- •Reference vessel diameter ≥ 2 mm and ≤ 7 mm by visual estimate.
- •Subject with ipsilateral/contralateral iliac disease that requires treatment during the index procedure can be included if treatment is successful (angiographic evidence of stenosis <30%). Iliac disease should be treated firstly by marketed devices excluding drug eluted stent and drug coated balloon.
- •Angiographic evidence of adequate distal run-off to the foot (at least one native calf vessel [posterior tibial, anterior tibial, or peroneal arteries] is patent, defined as < 50% diameter stenosis).
排除标准
- •Stroke or STEMI within 3 months prior to index procedure.
- •Either local or systemic thrombolytic therapy within 48 hours prior to index procedure.
- •Inability to tolerate oral anticoagulation therapy (blood thinners such as warfarin) while on concomitant dual antiplatelet therapy (DAPT).
- •Known allergies or sensitivities to heparin, aspirin (ASA), other anticoagulant/anti-platelet therapies, and/or paclitaxel or an allergy to contrast media that cannot be adequately pre-treated prior to the index procedure.
- •Breastfeeding women.
- •Chronic renal insufficiency with serum creatinine > 2.5 mg/dL within 14 days prior to index procedure.
- •White blood cell count (WBC) < 3,000 cells/mm3 within 14 days prior to index procedure.
- •Platelet count < 80,000 cells/mm3 or > 700,000 cells/mm3 within 14 days prior to index procedure.
- •Known or suspected active systemic infection evidenced by WBC > 14.0 (14000/mm3) within 14 days prior to index procedure.
- •Diagnosed with bleeding diatheses or hypercoagulable state.
- •Subject is enrolled in any investigational device, drug or biologic study.
- •Any major (e.g., cardiac. peripheral, abdominal) surgical procedure or planned intervention performed within 30 days prior to the index procedure.
- •Any major (e.g., cardiac. peripheral, abdominal) elective procedure or intervention within 30 days post index procedure.
- •Target lesion known in advance of enrollment to require treatment with alternative therapy such as (drug-eluting) stent, laser, atherectomy, cryoplasty, re-entry devices, cutting/scoring balloon, brachytherapy. Use of embolic protection devices is also prohibited.
- •Contralateral SFA/PPA disease requiring treatment in the same setting as index procedure.
- •Presence of additional lesions in the target vessel that require treatment during index procedure but do not meet the inclusion criteria.
- •Complete occlusion lesion> 100mm.
- •Target lesion is an in-stent or post-DCB restenosis or has been previously treated with bypass surgery.
- •Lesion within or adjacent to an aneurysm.
- •Acute or sub-acute thrombus in the target vessel.
- •Angiographic evidence of severe calcification.
- •Failure to successfully cross the target lesion with a guide wire.
- •Pre-dilation resulted in a major (≥ Grade D) flow-limiting dissection (observed on 2 orthogonal views) or residual stenosis > 70% or translesional peak gradient > 10mm Hg.
结局指标
主要结局
Major Adverse Events
时间窗: 12 months
a composite of device- and procedure-related mortality, major target limb amputation and clinically-driven target lesion revascularization（TLR） within 12-months post-initial procedure.
次要结局
- Secondary sustained clinical improvement(6 and 12 months)
- Duplex-defined binary restenosis (PSVR > 2.4) of the target lesion(6 and 12 months)
- Walking distance as assessed by 6 Minute Walk Test(at baseline, 30 days, 6 and 12 months)
- Procedural success(during the procedure)
- Death of any cause(30 days, 6 and 12 months)
- Target vessel revascularization(30 days, 6 and 12 months)
- Clinically-driven target vessel revascularization(30 days, 6 and 12 months)
- Major target limb amputation(30 days, 6 and 12 months)
- Thrombosis at the target lesion site(30 days, 6 and 12 months)
- Device success(during the procedure)
- Target lesion revascularization(30 days, 6 and 12 months)
- Clinically-driven target lesion revascularization(30 days, 6 and 12 months)
- Primary sustained clinical improvement(6 and 12 months)
- Walking capacity assessment by Walking Impairment Questionnaire(at baseline, 30 days, 6 and 12 months)
- Quality of life assessment by EuroQol Five Dimensions（EQ5D） questionnaire(at baseline, 30 days, 6 and 12 months)
- Clinical success(during the hospitalization)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
R3® Acetabular System in Patients With Degenerative Hip DiseaseOsteoarthritisNCT01407029Smith & Nephew, Inc.158
已完成
不适用
HAART Model 300 Annuloplasty RingAortic RegurgitationNCT01400841Biostable Science & Engineering18
终止
不适用
Prospective, multicentre, non randomized clinical study to investigate the safety and performance of the TIES III (Transcutaneous Implant Evacuation System) percutaneous titanium implant in patients undergoing surgery for permanent ileostomy or repair of a pre-existing permanent ileostomyPatients with ulcerative colitis, familial adenomatous polyposis coli, other diseases requiring elective coloproctectomy with a permanent ileostomyPatients with a failing conventional or continent ileostomyOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonACTRN12613000357752OstomyCure AS20
已完成
4 期
Prospective, randomized, controlled, multicenter pilot study investigating the therapy of increased blood pressure with help of a digital programI10I11I12I13Essential (primary) hypertensionHypertensive heart diseaseHypertensive renal diseaseHypertensive heart and renal diseaseDRKS00031923Vantis GmbH115
已完成
4 期
Prospective, randomized, controlled,multi-centre study on secondary prevention ofchronic ischemicheart disease through a digital programI25Chronic ischaemic heart diseaseDRKS00028081Vantis GmbH180